Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Dual human epidermal growth factor receptor 2 (HER2) blockade and hormonal therapy for the treatment of primary HER2-positive breast cancer: one more step toward chemotherapy-free therapy.

Literature DB >> 23569319

Dual human epidermal growth factor receptor 2 (HER2) blockade and hormonal therapy for the treatment of primary HER2-positive breast cancer: one more step toward chemotherapy-free therapy.

Aleix Prat, José Baselga.

Abstract

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2013 PMID： 23569319 DOI： 10.1200/JCO.2012.48.4998

Source DB: PubMed Journal: J Clin Oncol ISSN： 0732-183X Impact factor: 44.544

Keyword Cloud
Cited

× No keyword cloud information.

12 in total

1. Assessment of tumor characteristics and factors affecting survival in patients with primary metastatic breast carcinoma: a Multicenter Study of the Anatolian Society of Medical Oncology.

Authors: Ummugul Uyeturk; Berna Oksuzoglu; Tulay Akman; Ibrahim Turker; Nur Sener; Didem Tastekin; Oznur Bal; Veli Berk; Ulku Yalcintas Arslan; Zuhat Urakci; Cemil Bilir; Ugur Yilmaz; Dogan Yazilitas; Arife Ulas; Ozlem Uysal Sonmez; Burcin Budakoglu; Sener Cihan; Mukremin Uysal
Journal: Med Oncol Date: 2014-03-22 Impact factor: 3.064

2. Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer.

Authors: David Karnak; Carl G Engelke; Leslie A Parsels; Tasneem Kausar; Dongping Wei; Jordan R Robertson; Katherine B Marsh; Mary A Davis; Lili Zhao; Jonathan Maybaum; Theodore S Lawrence; Meredith A Morgan
Journal: Clin Cancer Res Date: 2014-08-12 Impact factor: 12.531

Review 3. Neoadjuvant therapy of early stage human epidermal growth factor receptor 2 positive breast cancer: latest evidence and clinical implications.

Authors: Sonia Pernas Simon
Journal: Ther Adv Med Oncol Date: 2014-09 Impact factor: 8.168

4. Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer.

Authors: Filippo Montemurro; Aleix Prat; Valentina Rossi; Giorgio Valabrega; Jeff Sperinde; Caterina Peraldo-Neia; Michela Donadio; Patricia Galván; Anna Sapino; Massimo Aglietta; José Baselga; Maurizio Scaltriti
Journal: Mol Oncol Date: 2013-09-13 Impact factor: 6.603

5. Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts.

Authors: Jolijn W Groeneweg; Silvia F Hernandez; Virginia F Byron; Celeste M DiGloria; Hector Lopez; Vanessa Scialabba; Minji Kim; Ling Zhang; Darrell R Borger; Rosemary Tambouret; Rosemary Foster; Bo R Rueda; Whitfield B Growdon
Journal: Clin Cancer Res Date: 2014-10-07 Impact factor: 12.531

Review 6. The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer.

Authors: Elisabeth J Diver; Rosemary Foster; Bo R Rueda; Whitfield B Growdon
Journal: Oncologist Date: 2015-06-22

7. HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant.

Authors: Whitfield B Growdon; Jolijn Groeneweg; Virginia Byron; Celeste DiGloria; Darrell R Borger; Rosemary Tambouret; Rosemary Foster; Ahmed Chenna; Jeff Sperinde; John Winslow; Bo R Rueda
Journal: Gynecol Oncol Date: 2015-01-17 Impact factor: 5.482